News

Published on

May 22, 2025

SeqOne Genomics Raises €20 Million in Oversubscribed Growth Round to Lead AI-Powered NGS Revolution in Personalized Medicine

New capital from Supernova Invest, alongside existing partners Elaia, Omnes, and Merieux Equity Partners, will accelerate SeqOne’s mission to transform genomic diagnostics worldwide, focusing on international expansion, U.S., and strategic growth.

‍

MONTPELLIER, France – May 22, 2025 – SeqOne, a pioneer in AI-driven genomic analysis for personalized medicine, today announced a significant €20 million oversubscribed growth funding round. Led by new investor Supernova Invest, with robust continued support from existing major investors Elaia, Omnes, and Merieux Equity Partners, this capital injection will fuel SeqOne's global expansion and solidify its leadership in transforming patient care through advanced genomic insights.

‍

This latest investment will be pivotal in SeqOne's mission to establish itself as the European champion in Next-Generation Sequencing (NGS) data analysis and interpretation for clinical diagnostics, with a clear ambition to become the world-leading software in this dynamic field, where the demand for precise and scalable genomic interpretation is accelerating globally. The financing also places SeqOne in a strong financial position, reinforcing its commitment to being a reliable, long-term partner for its customers.

‍

This funding will accelerate SeqOne’s strategic growth across three core pillars:

Global Expansion: Scale international operations further, building on significant momentum (3x customer growth to 140 labs in 22 countries in 12 months, over 110,000 patient analyses in 2025).
U.S. Market Acceleration: Intensifying U.S. operations following Q1 2025 market entry with SeqOne’s U.S.-dedicated, HIPAA-compliant platform.
Strategic Acquisitions: Continuing to pursue targeted acquisitions to expand capabilities and market share, such as the recent Life & Soft acquisition for its multi-omics expertise.

‍

"This fundraising is a testament to the incredible work of our team and the transformative potential of our platform in making personalized medicine a reality," said Martin Dubuc, CEO of SeqOne. "We are thrilled to welcome Supernova Invest and are deeply grateful for the continued trust of Elaia, Omnes, and Merieux Equity Partners. This new capital injection not only empowers us to scale our international operations, particularly with our US launch, and to further enhance our technological leadership, but it also fortifies our financial foundations, ensuring our customers can depend on us as a steadfast partner for years to come. Our goal is to equip every molecular laboratory with the most advanced, intuitive, and reliable genomic analysis solutions."

‍

Rémi Spagnol, Investment Director at Supernova Invest, commented, "SuperNova Invest is proud to partner with SeqOne, a company at the forefront of genomic analysis innovation. Their impressive growth, cutting-edge technology, and visionary leadership team give us strong conviction in their ability to become a global category leader. The market needs modern, automated, scalable solutions, and SeqOne is exceptionally well-positioned to meet this demand. We are excited to support their journey in revolutionizing how genetic data is used to improve patient outcomes and to help them build a true European champion with global reach."

‍

About SeqOne

SeqOne is a deep-tech company committed to making personalized medicine a reality. Its AI-powered genomic analysis platform provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analysis of genetic data for applications in oncology, rare diseases, and, through recent acquisitions, multi-omics, including pathogen detection. With 140 active lab customers across 22 countries and a projection to process over 110,000 patient analyses in 2025, SeqOne serves a growing global customer base of healthcare providers and biopharmaceutical companies, supported by strong industry partnerships and an expanding presence in the US market. www.seqone.com

‍

About Supernova Invest
Supernova Invest is the leading deeptech Venture Capital firm in Europe and manage c.€800 million in assets. The current portfolio includes 80+ innovative and impact-driven companies that develop products and services leveraging breakthrough technologies in 4 transition-centric sectors: Cleantech, Digital, Industrial Technologies and Healthcare. For 20 years, Supernova Invest has been providing long-term capital, operating experience, and strategic support to back sustainable growth of tomorrow’s deep tech and industrial champions throughout the Venture Capital life cycle: seed, early, late and growth stages. Supernova Invest also gathers the entire deep tech value chain to support portfolio companies: corporates, research institutions and co-investors.

Supernova Invest is backed both by Amundi, the largest asset manager in Europe, and CEA, the most innovative public research organization in Europe. www.supernovainvest.com

‍

About Elaia
Elaia is a European full stack tech and deep tech investor. We partner with ambitious entrepreneurs from inception to leadership, helping them navigate the future and the unknown. For over twenty years, we have combined deep scientific and technological expertise with decades of operational experience to back those building tomorrow. Our joint venture with Lazard, Lazard Elaia Capital, enables us to support exceptional founders at any stage. From our offices in Paris, Barcelona and Tel Aviv, we have been active partners with over 100 startups including Criteo, Mirakl, Shift Technology, AQEMIA and Alice & Bob. Learn more at elaia.com.

‍

About Omnes
Omnes is a leading private equity firm dedicated to energy transition. With over €6.7 bn in assets under management, our teams support long-term partnerships with entrepreneurs through our four core businesses: renewable energy, sustainable cities, deeptech and co-investment. For over 20 years, Omnes has been applying its expertise to help businesses grow in more than 15 countries, with a particular focus on sustainable development. As part of its approach as a responsible investor, the company has created the Omnes Foundation to support non-profit organisations working for children and young people in the fields of education, health, social and economic integration.
www.omnescapital.com

About Merieux Equity Partners
Mérieux Equity Partners (‘MxEP’) is an AMF-accredited investment firm specialising in the healthcare sector. With over €1.5 billion in assets under management through two dedicated strategies: Innovation and Buyout, MxEP supports companies ranging from start-ups to established leaders. Based in Lyon and Paris, with a strong industrial footprint, MxEP's team of healthcare specialists and investment professionals invests in European companies with significant growth and transformation potential. By providing financial and operational resources, MxEP enables businesses to achieve their goals and create value from innovative healthcare products and services which improve patient outcomes.

For more information, please visit www.merieux-partners.com

‍

Media contacts

SeqOne - Madeleine Latapie | madeleine.latapie@seqone.com

What’s new at SeqOne?

Platform features

May 7, 2025

SeqOne Launches SomaHemato: Advancing Precision in CLL Prognostics with Robust IGHV Mutational Status Analysis on the SeqOne Platform

SeqOne's SomaHemato offers robust, validated IGHV analysis for CLL prognosis, overcoming NGS short-read limits for precise clinical insights.

News

Apr 7, 2025

SeqOne Accelerates Growth and Expansion into Multi-Omics with Life & Soft Acquisition

Strategic acquisition bolsters SeqOne's multi-omics capabilities and expands service offerings with ISO-certified sequencing platform.

Platform features

Feb 10, 2025

Next-Generation Phenotype-Driven Genomic Analysis with SeqOne

SeqOne's DiagAI HPO automates extraction of HPO terms from clinical notes using AI, streamlining phenotype-driven genomic analysis with multi-language support.

Testimonial

Dec 5, 2024

Transforming Patient Care: SeqOne Empowers CHU de Reims with Advanced Genomic Analysis

Professor Anne-Sophie Lèbre of CHU de Reims uses SeqOne for rare disease and oncology genomics, enabling rapid, precise variant interpretation.

Science

Dec 5, 2024

Nanopore adaptive sampling accurately detects nucleotide variants and improves the characterization of large-scale rearrangement for the diagnosis of cancer predisposition

Here, 30 well-characterized clinical germline samples were studied with adaptive sampling to enrich the full sequence of 152 cancer predisposition genes. Sequencing was performed on Oxford Nanopore (ONT) R10.4.1 MinION flowcells with the Q20+ chemistry.

Platform features

Nov 18, 2024

SeqOne’s DiagAI Score Brings Transparency to Genomic Variant Ranking: Unveiling the AI Decision Process with xAI

DiagAI uses inheritance & quality rules based on real diagnostic data, enabling clinicians to understand AI recommendations and collaborate on system improvement.

News

Nov 14, 2024

SeqOne Platform Achieves IVDR Certification, Setting New Quality Standards for Clinical Genomic Analysis

SeqOne Platform gets IVDR Class C medical device certification for NGS analysis in oncology and rare diseases, validating quality and safety.

Case study

Oct 14, 2024

Precision Medicine at Scale: AP-HM’s Automated Exome Analysis Success Story

APHM and SeqOne partner to automate exome sequencing with AI, processing up to 2,000 rare disease samples yearly for better diagnostics.

Platform features

Oct 9, 2024

SeqOne Unveils DiagAI Score: Explainable AI-Powered Variant Ranking

SeqOne launches DiagAI Score, a 0-100 metric for ranking genetic variants' disease-causing potential, combining AI power with human expertise for faster diagnosis.

Science

Sep 30, 2024

Fine mapping of RNA isoform diversity using an innovative targeted long-read RNA sequencing protocol with novel dedicated bioinformatics pipeline

Solving the structure of mRNA transcripts is a major challenge for both research and molecular diagnostic purposes. Current approaches based on short-read RNA sequencing and RT-PCR techniques cannot fully explore the complexity of transcript structure.

Case study

Sep 9, 2024

Case Study: North West GLH Validation and Implementation of In-House HRD testing with SeqOne’s SomaHRD

SeqOne’s HRD platform enables North West GLH to conduct in-house genomic instability testing for ovarian cancer.

News

Jun 17, 2024

MGI Tech and SeqOne Partner to Advance End-to-End Genomic Analysis

MGI and SeqOne partner to develop genomic analysis solutions, combining MGI's sequencing tech with SeqOne's AI-powered platform.

Platform features

Jun 17, 2024

Introducing SeqOne CGH Array Interpretation

SeqOne Cloud now supports Agilent CGH MicroArrays, offering AI-powered CNV annotation, ACMG classification, and seamless Cartagenia migration.

Platform features

Apr 19, 2024

SeqOne GenomeAlert! A variant reevaluation automation agent to improve patient care

GenomeAlert! reevaluates genetic variant classifications monthly against ClinVar to ensure accurate patient diagnoses and treatment.

News

Mar 11, 2024

Oxford Nanopore Technologies and SeqOne Partner to Support Interpretation of Nanopore Sequencing in Clinical Use

A new partnership delivers end-to-end genome nanopore sequencing solutions for clinical applications in rare disease and oncology.

Science

Mar 1, 2024

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer

The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD).

News

Jan 30, 2024

SeqOne Genomics appoints Martin Dubuc as Chief Executive Officer

Martin Dubuc appointed as SeqOne Genomics CEO, Nicolas Philippe becomes President & CPSO to drive global clinical genomics expansion.

Platform features

Feb 22, 2023

SeqOne's Clinically Validated HRD Test Enhances Precision in Ovarian Cancer Treatment

SeqOne launches HRD test for ovarian cancer patients, validated with PAOLA-1 cohort. Clinical validation shows comparable survival benefits to Myriad myChoice® CDx.

Science

Nov 21, 2022

Genomic analysis of adult thrombotic microangiopathies in less than 3 days: from rapid to fast genomics to treatment

Using nanopore sequencing, we showed the feasibility and impact of rapid genomic screening for managing thrombotic microangiopathies in 18 prospective cases, achieving diagnoses in <3 days. We compared the results with standard exome sequencing, cost efficiency, and complement blockade initiation.

Science

Sep 22, 2022

Exome sequencing as a first-tier test for copy number variant detection: retrospective evaluation and prospective screening in 2418 cases

Despite the availability of whole exome (WES) and genome sequencing (WGS), chromosomal microarray (CMA) remains the first-line diagnostic test in most rare disorders diagnostic workup, looking for copy number variations (CNVs), with a diagnostic yield of 10%–20%.

Science

Jun 22, 2022

Rapid exome sequencing in critically ill infants: implementation in routine care from French regional hospital's perspective

This monocentric study included fifteen children under a year old in intensive care with suspected monogenic conditions for rapid trio exome sequencing (rES) between April 2019 and April 2021.

Science

Jun 4, 2022

Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation

Poly(ADP-ribose) polymerase 1 inhibitor (PARPi) agents can improve progression-free survival of patients with breast cancer who carry a germline BRCA1 or BRCA2 pathogenic or likely pathogenic variant (gBRCA) in both the metastatic and adjuvant setting.

Science

Mar 17, 2022

Genome Alert!: A standardized procedure for genomic variant reinterpretation and automated gene–phenotype reassessment in clinical routine

Retrospective interpretation of sequenced data in light of the current literature is a major concern of the field. Such reinterpretation is manual and both human resources and variable operating procedures are the main bottlenecks.

Science

Jun 23, 2021

Kmerator Suite: design of specific k-mer signatures and automatic metadata discovery in large RNA-seq datasets

The huge body of publicly available RNA-sequencing (RNA-seq) libraries is a treasure of functional information allowing to quantify the expression of known or novel transcripts in tissues.

Science

Sep 26, 2020

Clinical and Molecular Spectrum of Nonsyndromic Early-Onset Osteoarthritis

Osteoarthritis (OA) is the most common joint disease worldwide. The etiology of OA is varied, ranging from multifactorial to environmental to monogenic.

Science

Dec 28, 2017

DE-kupl: exhaustive capture of biological variation in RNA-seq data through k-mer decomposition

We introduce a k-mer-based computational protocol, DE-kupl, for capturing local RNA variation in a set of RNA-seq libraries, independently of a reference gen...

Science

Sep 29, 2017

SimBA: A methodology and tools for evaluating the performance of RNA-Seq bioinformatic pipelines

The evolution of next-generation sequencing (NGS) technologies has led to increased focus on RNA-Seq. Many bioinformatic tools have been developed for RNA-Seq analysis, each with unique performance characteristics and configuration parameters.